WHO international standard for SARS-CoV-2 antibodies to determine markers of protection

WHO international standard for SARS-CoV-2 antibodies to determine markers of protection

Bibliografske podrobnosti
Main Authors:	Zhu, F, Althaus, T, Tan, CW, Costantini, A, Chia, WN, Van Vinh Chau, N, Van Tan, L, Mattiuzzo, G, Rose, NJ, Voiglio, E, Wang, L-F
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2021

Podobne knjige/članki

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
od: Lidong Guan, et al.
Izdano: (2023-02-01)

WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community
od: Ivana Knezevic, PhD, et al.
Izdano: (2022-03-01)

Standardization of SARS-CoV-2 Nucleic Acid Amplification Techniques by Calibration and Quantification to the First WHO International Standard for SARS-CoV-2 RNA
od: Jolanda J. C. Voermans, et al.
Izdano: (2023-01-01)

Maritime Public Health Cross Border Cooperation: Principality of Monaco and Italian Liguria Health Port Authority Best Practices
od: Antonello Campagna, et al.
Izdano: (2022-12-01)

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
od: Jeewandara, C, et al.
Izdano: (2021)

Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins
od: Adam Leach, et al.
Izdano: (2021-05-01)

First clinical study of a new virus-inhibiting surgical glove
od: JL Caillot, et al.
Izdano: (2008-01-01)

Absence of SARS-CoV-2 antibodies in pre-pandemic plasma from children and adults in Vietnam
od: Chau, NVV, et al.
Izdano: (2021)

How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022
od: Thomas Althaus, et al.
Izdano: (2024-06-01)

Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody
od: Kuan-Ting Liu, et al.
Izdano: (2022-07-01)

Antibody Response following Exposure to SARS-CoV-2: Is It a Reliable Marker of Immunity?
od: Mona Dhakal, et al.
Izdano: (2022-04-01)

Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review
od: Andrea Lombardi, et al.
Izdano: (2022-12-01)

Expression of Embryonic Stem Cell Markers on the Microvessels of WHO Grade I Meningioma
od: Ganeshwaran Shivapathasundram, et al.
Izdano: (2018-10-01)

Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations
od: T. I. Smolyanova, et al.
Izdano: (2022-12-01)

Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors
od: F. A. Quee, et al.
Izdano: (2023-07-01)

Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants
od: Xuanxuan Zhang, et al.
Izdano: (2024-04-01)

SARS-CoV-2 spike S2-specific neutralizing antibodies
od: Chia-Jung Li, et al.
Izdano: (2023-12-01)

WHO expert committee on biological standardization
Izdano: (2006-04-01)

Evaluation of specific IgG antibody in subjects who had been previously infected with SARS-CoV-2
od: Soodabeh Rostami, et al.
Izdano: (2023-01-01)

Who benefits most?
od: L. Van Diermen
Izdano: (2021-04-01)

ANTIBODIES AGAINST THYROID AND THYROID STIMULATING HORMONE (TSH): WHO’S WHO?
od: Adina Ghemigian, et al.
Izdano: (2018-06-01)

Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
od: S. K. Pylaeva, et al.
Izdano: (2024-11-01)

No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
od: van Dorp, L, et al.
Izdano: (2020)

Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: Phylogenetic analysis and intervention scenarios.
od: Martina L Reichmuth, et al.
Izdano: (2023-08-01)

Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence
od: C. Bundschuh, et al.
Izdano: (2024-11-01)

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody
od: Emel Atayık, et al.
Izdano: (2022-10-01)

Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections
od: Ren Yang, et al.
Izdano: (2020-08-01)

Using Immunoglobulin G Spike Antibodies as a Surrogate Marker for SARS-CoV-2 Infection: Additional Considerations
od: Hinpetch Daungsupawong, PhD, et al.
Izdano: (2024-01-01)

Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection
od: Matthew S. Durstenfeld, et al.
Izdano: (2022-05-01)

Concorrência e Corrupção – Programas de Compliance no Debate Jurídico-Institucional Brasileiro
od: Marcela Mattiuzzo
Izdano: (2017-05-01)

ALGORITHMS AND BIG DATA: CONSIDERATIONS ON ALGORITHMIC GOVERNANCE AND ITS CONSEQUENCES FOR ANTITRUST ANALYSIS
od: Marcela Mattiuzzo

SARS-CoV-2 RNA and antibody dynamics in a Dutch household study with dense sampling frame
od: Wanda G. H. Han, et al.
Izdano: (2022-05-01)

New WHO child growth standards catch on

New WHO child growth standards catch on
Izdano: (2011-04-01)

WHO to develop new child growth standards
Izdano: (2004-09-01)

The WHO healthcare standards in the context of demographic processes
od: Małgorzata Pabiś, et al.
Izdano: (2018-12-01)

Circulating anti-retinal antibodies as immune markers in age-related macular degeneration.
od: Patel, N, et al.
Izdano: (2005)

Characterization of antibody interactions with the G protein of vesicular stomatitis virus Indiana strain and other vesiculovirus G proteins
od: Munis, A, et al.
Izdano: (2018)

Who is the sinner? The view of Karl Barth
od: F.J. van Zyl
Izdano: (2007-05-01)

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
od: Wang T, et al.
Izdano: (2022-10-01)